Idera Pharmaceuticals Announces Chief Financial Officer to Leave Company Effective July 31, 2007
21 Maggio 2007 - 3:20PM
Business Wire
Idera Pharmaceuticals (AMEX: IDP) today announced that Robert
Andersen, the Company�s Chief Financial Officer and Vice President
of Operations, will leave the Company on July 31, 2007 to pursue
personal interests after 10 years of service with the Company. Mr.
Andersen will remain with the Company through July 31, 2007 to
ensure a smooth and orderly transition for financial operations.
Idera has initiated a search for his successor. �Bob has provided
Idera with a decade of dedicated service during his tenure and has
been an integral member of the management team as the Company has
evolved into a leader in drug discovery and development targeting
toll-like receptors,� commented Sudhir Agrawal, D.Phil., Chief
Executive Officer and Chief Scientific Officer of Idera. �Everyone
at Idera and members of the Board of Directors of Idera thank Bob
deeply for his contributions and wish him the best in his next
endeavor.� About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals
is a drug discovery and development company that is developing drug
candidates to treat cancer and infectious, respiratory, and
autoimmune diseases, and for use as vaccine adjuvants. Idera�s
proprietary drug candidates are designed to modulate TLRs, the
body�s first line of immune defense. Idera�s pioneering DNA
chemistry expertise enables it to identify drug candidates for
internal development and creates opportunities for multiple
collaborative alliances. Idera�s most advanced clinical candidate,
IMO-2055, is an agonist of TLR9 and is currently in a Phase 2 trial
in oncology and in a Phase 1/2 chemotherapy combination trial in
oncology. Idera has selected a second TLR9 agonist, IMO-2125, as a
lead candidate for treating infectious diseases. Idera is
collaborating with Novartis International Pharmaceutical, Ltd. for
the discovery, development, and commercialization of TLR9 agonists
for the treatment of asthma and allergy indications. Idera is also
collaborating with Merck & Co., Inc. for the use of Idera�s
TLR7, 8 and 9 agonists in combination with Merck�s therapeutic and
prophylactic vaccines in the areas of oncology, infectious
diseases, and Alzheimer�s disease. For more information, visit
www.iderapharma.com. Forward Looking Statements This press release
contains forward-looking statements concerning Idera
Pharmaceuticals, Inc. that involve a number of risks and
uncertainties. For this purpose, any statements contained herein
that are not statements of historical fact may be deemed to be
forward-looking statements. Without limiting the foregoing, the
words "believes," "anticipates," "plans," "expects," "estimates,"
"intends," "should," "could," "will," "may," and similar
expressions are intended to identify forward-looking statements.
There are a number of important factors that could cause Idera�s
actual results to differ materially from those indicated by such
forward-looking statements, including whether products based on
Idera�s technology will advance into or through the clinical trial
process on a timely basis or at all and receive approval from the
United States Food and Drug Administration or equivalent foreign
regulatory agencies; whether, if the Company�s products receive
approval, they will be successfully distributed and marketed;
whether the Company�s collaborations with Novartis and Merck will
be successful; whether Idera�s cash resources will be sufficient to
fund product development and clinical trials; and such other
important factors as are set forth under the caption "Risk Factors"
in Idera�s Quarterly Report on Form 10-Q filed on May 14, 2007,
which important factors are incorporated herein by reference. Idera
disclaims any intention or obligation to update any forward-looking
statements.
Grafico Azioni Idera Pharmaceutical (AMEX:IDP)
Storico
Da Ago 2024 a Set 2024
Grafico Azioni Idera Pharmaceutical (AMEX:IDP)
Storico
Da Set 2023 a Set 2024
Notizie in Tempo Reale relative a Idera Pharmaceuticals (Borsa Americana (AMEX)): 0 articoli recenti
Più Idera Pharmaceuticals Articoli Notizie